What type of study is this?

This is a In Vitro Study study (also classified as: Validation Study).

What question did this study set out to answer?

To develop a laboratory-based tool for diagnosing cachexia and predicting survival in patients with Acute Myeloid Leukemia and myelodysplastic syndrome.

December 8, 2025Blood

The cachexia hematologic severity score (CHeSS): Use of a laboratory-based tool to predict survival and mutation-associated wasting in Acute Myeloid Leukemia and myelodysplastic syndrome

View Full Paper

Ask AI

Bookmark

Authors

ARAnisha Rajavel SRSushmitha Nanja Reddy DPDakshin Padmanabhan

Discussion

Member takes

Overview

Prediction of cachexia severity and survival outcomes in Acute Myeloid Leukemia and myelodysplastic syndrome patients suggests a need for early intervention.

Key Points

To develop a laboratory-based tool for diagnosing cachexia and predicting survival in patients with Acute Myeloid Leukemia and myelodysplastic syndrome.
Retrospective analysis of 203 adult patients with MDS, pAML, and sAML at Karmanos Cancer Institute
Assessment of laboratory markers: total protein, albumin, creatine, weight, and BMI
Development of Cachexia Hematologic Severity Score using defined scales
51% had MDS, 49% had AML with survival rates linked to cachexia severity
Median overall survival was significantly lower in cachectic patients (13 months) compared to non-cachectic (102 months)
Statistically significant mutation associations with cachexia severity noted with mutations like TP53 and ASXL1.

Cite This Study

Rajavel et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0a9 https://doi.org/10.1182/blood-2025-1735

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

The cachexia hematologic severity score (CHeSS): Use of a laboratory-based tool to predict survival and mutation-associated wasting in Acute Myeloid Leukemia and myelodysplastic syndrome

View Full Paper

Ask AI

Bookmark

Authors

ARAnisha Rajavel SRSushmitha Nanja Reddy DPDakshin Padmanabhan

Discussion

Member takes

Overview

Prediction of cachexia severity and survival outcomes in Acute Myeloid Leukemia and myelodysplastic syndrome patients suggests a need for early intervention.

Key Points

To develop a laboratory-based tool for diagnosing cachexia and predicting survival in patients with Acute Myeloid Leukemia and myelodysplastic syndrome.
Retrospective analysis of 203 adult patients with MDS, pAML, and sAML at Karmanos Cancer Institute
Assessment of laboratory markers: total protein, albumin, creatine, weight, and BMI
Development of Cachexia Hematologic Severity Score using defined scales
51% had MDS, 49% had AML with survival rates linked to cachexia severity
Median overall survival was significantly lower in cachectic patients (13 months) compared to non-cachectic (102 months)
Statistically significant mutation associations with cachexia severity noted with mutations like TP53 and ASXL1.

Cite This Study

Rajavel et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0a9 https://doi.org/10.1182/blood-2025-1735

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark